Terminated PHASE2 INTERVENTIONAL 2-arm NCT01170949

Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria (MIARCU)

Randomised, Double-blind, Placebo-controlled Study

Sponsor: Charite University, Berlin, Germany

Updated 7 times since 2017 Last updated: Nov 1, 2016 Started: Sep 30, 2008 Primary completion: Sep 30, 2008 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study medication expired

Other terminated trials from Charite University, Berlin, Germany

See all terminations from Charite University, Berlin, Germany

Other Chronic Urticaria trials with similar outcome

Browse all Chronic Urticaria trials

A PHASE2 clinical study on Chronic Urticaria, this trial is terminated or withdrawn. The trial is conducted by Charite University, Berlin, Germany and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany
Marcus Maurer

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany